Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on August 8, 2018. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, California. The filing serves to disclose a corporate presentation used by management at investor conferences.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to attach a presentation and does not contain a financial statement or earnings release.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing solely references the distribution of a corporate presentation (Exhibit 99.1) as a Regulation FD disclosure.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in the attached presentation (Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated. Consequently, no specific guidance, outlook, or risk factors are detailed within the text of this 8-K itself.
Key Facts for Investor Verification
- Verify the actual content of the attached Exhibit 99.1 (Corporate Presentation dated August 2018) for any forward-looking statements or strategic updates, as the 8-K text only references its existence.
- Confirm that the registrant is Imprimis Pharmaceuticals, Inc., noting the discrepancy with the metadata label "HARROW, INC."
- Understand that the attached presentation is not legally "filed" with the SEC and carries different liability standards than the 8-K itself.